3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement

This manuscript reports on the 3-year follow up results of the CoreValve US Pivotal Trial in which patients with aortic stenosis at high risk for surgery were randomly assigned to self-expanding TAVR or SAVR in a 1:1 manner. At 3 years, the results of this analysis demonstrate a sustained 3-year clinical benefit of TAVR with a self-expanding prosthesis over SAVR. There was a reduction in all-cause mortality and stroke. TAVR was also shown to have lower 3-year mean aortic valve gradients and larger effective orifice areas compared with SAVR. Moderate or severe AR was higher with TAVR compared with SAVR. There were no differences in the occurrence of structural valve deterioration over time in the 2 groups.